Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, ...
You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...
GLP-1 weight loss drugs such as Ozempic are on the rise. While their use is initially most prominent in the US, many predict ...
Lawmakers are floating a compromise to break an impasse on legislation that would hamper Chinese biotech firms’ ability to do ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 525.52% and ...
Rep. Brad Wenstrup, R-Ohio, said his bill on the topic creates a more holistic approach than simple government coverage by ...
Eli Lilly and Company announced a significant expansion at its Pleasant Prairie facility Thursday. The pharmaceutical giant plans a $3 billion investment, which is expected to create 750 new jobs at ...
It appears not all weight-loss drugs are created equal. The users of one drug report more weight loss comparted to another ...
DealBook Summit, Lilly CEO David Ricks said GLP-1 drugs have the potential to treat more than obesity — including heart disease and substance use disorders.
Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its ...